Over the last two quarters, Immuron (IMC: $0.085) sales have increased from $1.3 million to $1.5 million and most recently to $2.5 million from its core Travelan product, used to prevent traveler's diarrhea.

In the first half of this financial year, sales were up 70% overall over the PCP to $4.0 million. The growth came from both Australia (up 54% on PCP) and North America (up 130% on PCP). The split between Australian and North American sales were 73%/27%.

Sales in FY2025 are set to eclipse sales in 2024 and 2023 which were $4.9 million and $1.8 million respectively. The company sells through pharmacies in Australia and Canada and via Amazon in the US.

Immuron is capitalized at $20 million with $11.7 million in cash at the end of June last year.